TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Monday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). The company had revenue of $8.26 million for the quarter, compared to analyst estimates of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Stock Up 2.2 %

TLSI stock opened at $5.62 on Monday. The business has a fifty day moving average of $5.40 and a 200-day moving average of $4.73. The company has a market cap of $171.37 million, a P/E ratio of -2.26 and a beta of 0.48. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.42.

Analyst Upgrades and Downgrades

TLSI has been the topic of a number of research reports. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday. Roth Mkm reaffirmed a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Lake Street Capital began coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a “buy” rating and a $10.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $11.56.

Insider Buying and Selling

In related news, insider Sean Murphy purchased 15,000 shares of TriSalus Life Sciences stock in a transaction dated Monday, January 27th. The stock was bought at an average price of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the acquisition, the insider now directly owns 182,732 shares of the company’s stock, valued at $970,306.92. This represents a 8.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mary T. Szela acquired 4,826 shares of the stock in a transaction dated Monday, January 27th. The shares were bought at an average cost of $5.42 per share, with a total value of $26,156.92. Following the transaction, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 54,856 shares of company stock valued at $294,608. 32.80% of the stock is owned by company insiders.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.